Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I mean just look at the chart under the ‘Efficacy in an in vivo PDX model of Osteosarcoma’ section on the poster!
Figure 5: Heavily pre-treated human sarcoma model, AVA6000 at 12 mg/kg significantly decreased tumor volume while doxorubicin at 2 mg/kg had no significant effect
AVA6K dosed at SIX times higher than Doxorubicin and yielding SIGNIFICANTLY better results. Oh and by the way, Doxorubicin is only an approved, market leading anti-cancer treatment ;)
I know!!! This is MAJOR
'Dox concentration was only detected in FAP enzyme.'
The statement above was taken from the poster and made based off AVA6000 Doxorubicin trials. It clearly spells out that Avacta’s proprietary targeted chemotherapy platform, releases active drug only in the tumour. By doing this, AVA6000 would limit the systemic exposure and improve the overall safety and therapeutic potential of Doxorubicin; a powerful anti-cancer treatment with a market size that is expected to grow to $1.38bn by 2024.
Let that sink in
Can we just pause whilst it’s quiet on here for a recap of the, quite simply INCREDIBLE, news highlighted on the poster snippet:
One of the pre-clinical in vivo bone cancer studies that Avacta performed, involved the grafting of HUMAN tumor cells within mice (PDX model of osteosarcoma). The results: “AVA6k significantly reduced tumor volume while Doxorubicin had no significant effect”.
The studies involved HUMAN cells!! Whereby, AVA6k was 80-4000 times LESS toxic to living cells than Doxorubicin!!!
Let that sink in!!! 80-4000 times!!!
HAHA very good PL45, made me chuckle on a Wednesday morning
See below statement from the FDA, re. one of the LFT’s that the UK Government have been handing out to the public...
Date Issued: March 1, 2022
The U.S. Food and Drug Administration (FDA) is warning people not to use certain ACON COVID-19 tests, a product of ACON Biotech (Hangzhou) Co., Ltd. People should not use the ACON Biotech test named “Flowflex SARS-CoV-2 Antigen Rapid Test (Self-Testing)” that is packaged in a dark blue box. This test has not been authorized, cleared, or approved by the FDA for distribution or use in the United States. The FDA is concerned about the risk of false results when using this unauthorized test.
https://www.gov.uk/government/publications/coronavirus-covid-19-rapid-lateral-flow-home-test-kit-instructions-for-nose-only-test-acon-flowflex
https://www.fda.gov/medical-devices/safety-communications/do-not-use-certain-acon-flowflex-covid-19-tests-fda-safety-communication
Don’t forget that the AVA6000 trial has transformed Avacta into a clinical stage company. Of which we are 7 months in and a world renowned NED has joined, quoting words such as “Great promise” in relation to the preCISION platform and “disruptive” in relation to it’s potential effect in the oncology field. If the AVA6000 study shows that the preCISION chemistry is effective in reducing systemic toxicity of doxorubicin in humans, then it can be applied to a range of other established chemotherapies to improve their safety and efficacy. This would open up a pipeline of next generation chemotherapies for Avacta with significant clinical and commercial value in a chemotherapy market that is expected to grow to $56 billion by 2024
Newly appointed AVCT NED, Christina Coughlin, Tweeted this today from her personal account:
“Excited to join the Board @avacta The Affimer and preCISION platforms hold great promise for patients and are potentially disruptive in the oncology field. Looking forward to working with new and old colleagues @EliotForster #AlastairSmith”
Surely, a statement like this couldn’t have been made without having seen the trial data so far...
https://twitter.com/coughlin582/status/1506265269013925897?s=21
Avacta has received an upfront payment of £0.9 million and will receive additional deferred consideration of up to £1.4 million dependent on the combined performance of the consolidated business. The Animal Health Division had made an operating loss (prior to an impairment of historic goodwill) of £0.3 million during the year ended 31 December 2020. The carrying value of the Division as at 31 December 2020 was £1.0 million. The sale proceeds will provide further funds for the development of the Group's Diagnostics and Therapeutics Divisions.
I don’t think anyone can complain with that, Especially considering what the proceeds are going towards. Onwards and upwards
A reminder of the AffyXell venture, which last year attracted $7.3 million to further develop its pipeline. (Remember, these funds were raised from a group of venture funds including Samsung Venture Investment Corporation, Shinhan Venture Investment, Smilegate Investment, Shinhan Investment Corporation, Kolon Investment, Stonebridge Ventures, and Gyeongnam Venture Investment.)
AffyXell was established in January 2020 by Avacta and Daewoong as a Joint Venture to develop novel mesenchymal stem cell (MSC) therapies. AffyXell is combining Avacta's Affimer platform with Daewoong's MSC platform such that the stem cells are genetically modified to produce and secrete therapeutic Affimer proteins in situ in the patient. The Affimer proteins are designed to enhance the therapeutic effects of the MSC creating a novel, next generation cell therapy platform.
I’ll leave you with a comment from Sengho Jeon, (Chief Executive Officer of Daewoong Pharmaceutical and AffyXell Therapeutics) himself:
"AffyXell's successful Series A financing confirms the market's high expectations and interest in new MSC therapies. It is also very encouraging that the concept of this joint venture, which was established based on the excellent platform technologies of Daewoong Pharmaceutical and Avacta, gains recognition for its vision among venture funds.
Believe in your investment
Daewoong Pharmaceutical/Avacta (Affyxell Therapeutics) said they would cooperate with Seoul National University Hospital (SNUH) in developing regenerative medicine and advanced biopharmaceuticals.
Daewoong CEO Jeon Seng-ho (fourth from left), Affyxell Therapeutics CEO Yoo Jong-sang (at Jeon's left), and SNUH President Kim Yeon-soo (at Jeon's right) celebrate signing the agreement to cooperate in developing regenerative medicine at Seoul National University Hospital in Jongno-gu, Seoul, on Monday.
Daewoong CEO Jeon Seng-ho (fourth from left), Affyxell Therapeutics CEO Yoo Jong-sang (at Jeon's left), and SNUH President Kim Yeon-soo (at Jeon's right) celebrate signing the agreement to cooperate in developing regenerative medicine at Seoul National University Hospital in Jongno-gu, Seoul, on Monday.
The three have signed a memorandum of understanding to establish a regenerative medical infrastructure and cooperate in clinical research on advanced biopharmaceuticals.
Under the accord, they will cooperate to conduct Korean and foreign research projects, discover, preserve and industrialize intellectual properties, build a world-class competitive regenerative medical infrastructure. They will also collaborate in clinical research and development of advanced biopharmaceuticals, technology exchange, and the education of research personnel.
Daewoong and Affyxell expect that the cooperation with SNUH, Korea's top medical institution, will help accelerate the development of advanced biopharmaceuticals.
Last year, Daewoong entered the advanced biopharmaceutical consignment development and production business after receiving approval from the Ministry of Food and Drug Safety.
Affyxell Therapeutics, a joint venture between Daewoong Pharmaceutical and Avacta, a U.K.-based pharmaceutical firm, is also developing a next-generation cell that enhances effectiveness by grafting Daewoong's stem cell platform (DW-MSC) to Avacta's Affimer technology.
"It is reassuring to work with SNUH, the best medical institution in Korea, in the fields of regenerative medicine and advanced biopharmaceuticals, which are representative future growth engines in the pharmaceutical field," Daewoong CEO Jeon Seng-ho said. "Based on this MOU, we will contribute to improving the quality of life of the people by further devoting ourselves to R&D."
SNUH President Kim Yeon-soo said, "We are delighted to borrow the cutting-edge R&D capabilities of Daewoong Pharmaceutical and Affyxell in the biopharmaceutical field."
Through this cooperation, we will accelerate the establishment of a world-class competitive regenerative medical infrastructure and clinical research and development, Kim added
http://www.koreabiomed.com/news/articleView.html?idxno=13252
Interesting to see that the person who has increased their holding by the largest margin recently is Richard Hughes....Co-Founder of Medusa19
Yes this is correct and what I do on all my major holdings. Be prepared for a call from your broker though to "clarify that your high sell order is correct and that you want to sell at that price". Just confirm it is correct. Job done.
Would be worth keeping an eye on companies house to see if JC closes any of his other appointments:
https://find-and-update.company-information.service.gov.uk/officers/IkYDSkQXyY1oZG_qmx5bbUk7Luk/appointments
Yes, Jupiter reduced their short yesterday (01/03/2022) by another -0.20%. Lowering their short position to: 0.68% (previously 0.88%/1.03% on 3rd Feb)
Also, some chunky aftermarket buys today (107,832 shares, 111,185 shares, 111,185 shares)
Cubosomes are porous lyotropic liquid crystalline nanoparticles that have shown great premise as drug delivery vehicles. Cubosomes are porous lyotropic liquid crystalline nanoparticles that have shown great premise as drug delivery vehicles.
A must read article released yesterday (23rd Feb 2022), outlining the first preclinical investigation of Affimer targeted cubosomes as a cancer therapeutic!
https://pubs.acs.org/doi/full/10.1021/acsami.1c21655
The work involved and yielded the below findings:
1. engineered cubosomes
2. functionalized with Affimer proteins via copper-free click chemistry to actively target overexpressed carcinoembryonic antigens on LS174T colorectal cancer cells
3. Affimer tagged cubosomes showed preferential accumulation in cancer cells compared to normal cells not only in vitro (2D monolayer cell culture and 3D spheroid models) but also in vivo in colorectal cancer mouse xenografts
4. exhibiting low nonspecific absorption and toxicity in other vital organs
5. Cancerous spheroids had maximum cell death compared to noncancerous cells upon targeted delivery.
6. targeted drug-loaded cubosomes showed a 5–7-fold higher drug accumulation in the tumor tissue compared to the liver, kidneys, and other vital organs, a significant decrease in tumor growth
No quote for 1000 shares on HALI (09:17)
Really sorry to hear of your losses EGTP and send my sincere condolences. I too lost my closest friend to the Big C. He was just 35 and had his whole life ahead of him. I am sure cancer has touched the lives of many people on this board, and truly hope that this company we are invested in, is able to contribute positively to the fight against this truly awful disease.
Yes, prior to the ongoing pandemic, Lateral Flow Assay tests had already proved valuable in testing against other disease outbreaks including Zika, Ebola and Malaria5,6,7. In fact, a report by the WHO in 2017 found that 2.7 billion rapid tests for Malaria were sold in 2010 -2019